Bevirimat dimeglumine: Phase IIb started

Myriad began an open-label Phase IIb trial to evaluate 300 or 400 mg of oral MPC-4326 given twice daily in combination with antiretroviral (ARV) therapy in 300 HIV-1 patients demonstrating ARV resista...